Here are the DEF 14A proxy statements from Syndax Pharmaceuticals, Inc. (SNDX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow SNDX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SNDX filings page.
Syndax Pharmaceuticals is asking stockholders to vote at its 2026 virtual annual meeting on June 10, 2026 at 12:00 p.m. EDT. Holders of 88,595,948 common shares as of April 21, 2026 may participate online via meetnow.global/MUGAWRX.
Stockholders will elect two Class I directors (Pierre Legault and CEO Michael A. Metzger) to terms ending in 2029, cast an advisory say-on-pay vote on named executive officer compensation, and ratify Deloitte & Touche LLP as independent auditor for 2026.
The agenda also includes approval of a new 2026 Equity Incentive Plan covering 7,200,000 shares and a new 2026 Employee Stock Purchase Plan, both intended to support ongoing talent attraction, retention and alignment with long-term stockholder value.